Actinium Pharmaceuticals (ATNM) Investor presentation summary

Investment highlights and strategic positioning

• Multi-asset radiotherapy pipeline at an inflection point, with key data readouts expected in 2026 and a cash runway into 2028 supported by $48 million in cash and no debt or warrants outstanding.

• Focus on first-in-class therapies for solid tumors (prostate, lung, breast) and hematologic malignancies, targeting large, underserved markets.

• Positioned to address the innovation gap in radiopharmaceuticals, with robust R&D, in-house manufacturing, and approximately 250 patents including Ac-225 production technology.

• Expanding manufacturing capabilities with a new facility operational in 2H 2026 and a supply chain established at ~50 leading hospitals.

Pipeline and clinical development

• ATNM-400 is a first-in-class Ac-225 radiotherapy with pan-tumor potential, showing robust preclinical efficacy in mCRPC, NSCLC, and breast cancer, and synergy with existing therapies.

• Actimab-A targets MDSCs to potentially enhance immunotherapy efficacy, with a Phase 1 basket trial in MDSC-rich tumors expected to yield data in 2H 2026.

• Hematology franchise includes late-stage Actimab-A and lomab-B, both Phase 2/3 ready, addressing the full AML treatment journey and universal conditioning for cell and gene therapies.

• Multiple clinical trials ongoing or planned, including for CAR-T and sickle cell disease conditioning, with initial data expected in 2026.

Market opportunities and differentiation

• ATNM-400 addresses blockbuster segments in prostate cancer (100,000+ patient opportunity), NSCLC, and breast cancer, outperforming current standards in preclinical models.

• Actimab-A could unlock a $40+ billion PD-1 market by depleting MDSCs and expanding immunotherapy indications.

• Hematology assets target 110,000 patients in the US and EU, with strong commercial dynamics and concentrated treatment centers.

• Strategic focus on novel, differentiated assets to fill pharma's pipeline gaps, leveraging industry M&A trends and underutilized infrastructure.